Michael W. Bishop
YOU?
Author Swipe
View article: ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma
ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma Open
Study Aim: Patients with high-risk Ewing sarcoma (ES) have dismal outcomes despite aggressive multimodal therapy. This phase II, single-institution study evaluated the response rate to two up-front cycles of irinotecan, temozolomide, and t…
View article: Comparing Whole-Body Diffusion-weighted MRI to Conventional Imaging: Staging Pediatric Bone and Soft-Tissue Sarcomas
Comparing Whole-Body Diffusion-weighted MRI to Conventional Imaging: Staging Pediatric Bone and Soft-Tissue Sarcomas Open
Whole-body diffusion-weighted MRI demonstrated agreement with conventional imaging and higher lesion sensitivity but lower specificity than PET/CT in staging pediatric bone and soft-tissue sarcomas.
View article: Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors
Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors Open
Background Multitargeted tyrosine kinase inhibitors (MTKIs) have increasingly been used for the treatment of pediatric and young adult patients with solid tumors. Whereas cardiac toxicity is documented in adults, data remain limited in ped…
View article: Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer Open
View article: Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment
Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment Open
Background Patients with bilateral Wilms tumor initially receive neoadjuvant chemotherapy to shrink the tumors and increase the likelihood of successful nephron-sparing surgery. Biopsy of poorly responding tumors is often done to better un…
View article: Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer Open
View article: Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer Open
View article: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
A joint international consensus statement for measuring quality of survival for patients with childhood cancer Open
View article: <sup>18</sup>F-FDG PET/CT in the Management of Osteosarcoma
<sup>18</sup>F-FDG PET/CT in the Management of Osteosarcoma Open
Osteosarcoma is the most common type of primary malignant bone tumor. 18F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the cli…
View article: Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma Open
Tables of antibody infusion times and Curie Scores
View article: Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma Open
Purpose:We sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children with newly diagnosed high-risk neuroblastoma.Patients and M…
View article: Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma Open
Purpose:We sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children with newly diagnosed high-risk neuroblastoma.Patients and M…
View article: Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma Open
Tables of antibody infusion times and Curie Scores
View article: Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas Open
View article: Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care
Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care Open
Survival for pediatric patients diagnosed with cancer has improved significantly. This achievement has been made possible due to new treatment modalities and the incorporation of a systematic multidisciplinary approach for supportive care.…
View article: Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long‐term consequences
Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long‐term consequences Open
Background Data on primary hypothyroidism and its long‐term impact on the health, cognition, and quality of life (QOL) of childhood cancer survivors are limited. This study examined the prevalence of and risk factors for primary hypothyroi…
View article: Robust method of determining microfacet BRDF parameters in the presence of noise via recursive optimization
Robust method of determining microfacet BRDF parameters in the presence of noise via recursive optimization Open
Accurate bidirectional reflectance distribution function (BRDF) models are essential for computer graphics and remote sensing performance. The popular microfacet class of BRDF models is geometric-optics-based and computationally inexpensiv…
View article: Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force Open
Osteosarcoma is the most common bone tumor in children and young adults. Metastatic and relapsed disease confer poor prognosis, and there have been no improvements in outcomes for several decades. The disease's biological complexity, lack …
View article: Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors Open
Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recomme…
View article: Pain and functional outcomes in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study
Pain and functional outcomes in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study Open
Background Although survivors of childhood cancer are at risk of chronic pain, the impact of pain on daily functioning is not well understood. Methods A total of 2836 survivors (mean age, 32.2 years [SD, 8.5 years]; mean time since diagnos…
View article: RIGHT ATRIAL MALIGNANT ANGIOSARCOMA WITH PULMONARY METASTASIS
RIGHT ATRIAL MALIGNANT ANGIOSARCOMA WITH PULMONARY METASTASIS Open
View article: Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study
Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study Open
Background: Adult survivors of childhood osteosarcoma and Ewing sarcoma are at risk of developing therapy-related chronic health conditions. We characterized the cumulative burden of chronic conditions and health status of survivors of chi…
View article: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma Open
Purpose Patients with cancer receiving tumor-reactive humanized monoclonal antibody (mAb) therapy can develop a human antihuman antibody (HAHA) response against the therapeutic mAb. We evaluated for HAHA in patients with neuroblastoma trea…
View article: Neurocognitive and psychosocial outcomes in adult survivors of childhood soft‐tissue sarcoma: A report from the St. Jude Lifetime Cohort
Neurocognitive and psychosocial outcomes in adult survivors of childhood soft‐tissue sarcoma: A report from the St. Jude Lifetime Cohort Open
Background To the authors' knowledge, few studies to date have examined long‐term neurocognitive outcomes in survivors of childhood soft‐tissue sarcoma. Methods A total of 150 survivors (41% of whom were female with a mean current age of 3…
View article: A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors Open
Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/ref…
View article: A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma Open
Purpose: We sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children with newly diagnosed high-risk neuroblastoma. Patients and…
View article: Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study
Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study Open
PURPOSE Direct assessment of Leydig cell function in childhood cancer survivors has been limited. The objectives of this study were to describe the prevalence of and risk factors for Leydig cell failure (LCF), Leydig cell dysfunction (LCD)…
View article: Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group Open
Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we ente…
View article: Curative‐intent radiotherapy for pediatric osteosarcoma: The St. Jude experience
Curative‐intent radiotherapy for pediatric osteosarcoma: The St. Jude experience Open
Background Radiation therapy (RT) confers local tumor control and survival advantages in some patients with osteosarcoma, yet pediatric and adolescent and young adult (AYA) population studies are limited. Methods Twenty‐eight patients trea…
View article: Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Open